Carfilzomib experience in relapsed/refractory multiple myeloma: a single-center experience

Basit Öğe Kaydı
dc.contributor.authorUysal, Ayşe
dc.contributor.authorSoyer, Nur Akad
dc.contributor.authorÖzkan, Melda
dc.contributor.authorŞahin, Fahri
dc.contributor.authorVural, Filiz
dc.contributor.authorTöbü, Mahmut
dc.contributor.authorSaydam, Güray
dc.date.accessioned2020-12-01T12:32:56Z
dc.date.available2020-12-01T12:32:56Z
dc.date.issued2018
dc.departmentEge Üniversitesien_US
dc.description.abstractBackground/aim: Carfilzomib (CFZ) is a new-generation proteasome inhibitor with significant activity in relapsed or refractory multiple myeloma (R/R-MM). We have retrospectively evaluated R/R-MM patients who were treated with CFZ plus dexamethasone. Materials and methods: Twenty-one R/R-MM patients who were treated with CFZ plus dexamethasone between October 2013 and January 2016 were screened. the patients were followed until March 2016 after CFZ treatment. Results: Ten (47.6%) of the patients were female and 11 (52.4%) of them were male. the median age was 62 (47–76) years. the median number of prior treatment lines was 3 (2–7). the median number of administered cycles of treatment for CFZ was 4 (1–10). the median overall response rate was 26.3%. the most common hematological adverse events were anemia and thrombocytopenia (38%). the most common nonhematological adverse event was fatigue (71.4%). One patient died because of a cerebrovascular event and 1 patient died because of pneumonia during the treatment period. the median duration of response rate and time to next therapy were 8 (7–9) and 3 (2–16) months, respectively. the median overall survival was 8 (0.5–33) months. Conclusion: Despite the small number of patients, our results suggest that CFZ provides acceptable responses in heavily pretreated R/R-MM patients.en_US
dc.identifier.doi10.3906/sag-1611-97
dc.identifier.endpage83en_US
dc.identifier.issn1300-0144
dc.identifier.issn1303-6165
dc.identifier.issue1en_US
dc.identifier.startpage80en_US
dc.identifier.urihttps://doi.org/10.3906/sag-1611-97
dc.identifier.urihttps://app.trdizin.gov.tr//makale/TWprNU1USXhNUT09
dc.identifier.urihttps://hdl.handle.net/11454/66396
dc.identifier.volume48en_US
dc.indekslendigikaynakTR-Dizinen_US
dc.language.isoenen_US
dc.relation.ispartofTurkish Journal of Medical Sciencesen_US
dc.relation.publicationcategoryMakale - Ulusal Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectCerrahien_US
dc.titleCarfilzomib experience in relapsed/refractory multiple myeloma: a single-center experienceen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

TR-Dizin İndeksli Yayınlar Koleksiyonu